2003 Pharmaceuticals Targeted Protein Degradation Therapies 
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess.
Drug Target Review
OCTOBER 4, 2023
Recent efforts are breathing new life into geldanamycin through the construction of a fusion protein made with an anti-HER2 scFv and an HSP90 inhibitor-binding domain (HER2 scFv-HBD), which has resulted in improved anti-cancer efficacy in HER2-positive cancers when loaded with geldanamycin derivatives. 1 , 33–43 (2018). 102 , 1–6 (2016).
Expert insights. Personalized for you.
189 
Let's personalize your content